IP Library Granted Patent US 11,033,661
Granted Patent B2
US 11,033,661 · App. 15/556,776 · Granted Jun 15, 2021

Anti-adhesion material and substitute biomembrane using decellularized tissue

Inventors: Hideki Saga (Koshi, JP); Takanori Uchida (Kumamoto, JP); Shoko Tokorozaki (Shikokuchuo, JP); Ken-ichiro Hiwatari (Tokyo, JP); Haruki Obara (Kamisu, JP); Akio Kishida (Tokyo, JP); Tsuyoshi Kimura (Tokyo, JP); Jun Negishi (Ueda, JP); Tetsuya Higami (Sapporo, JP); Seiichi Funamoto (Tokyo, JP)
Assignees: ADEKA CORPORATION; NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY; SAPPORO MEDICAL UNIVERSITY
A61L31/046A61L31/005A61L31/10A61L24/106A61L2300/424
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,033,661
App. No.
15/556,776
Granted
Jun 15, 2021
Kind
B2
Abstract

An anti-adhesion material comprising decellularized tissues and a biocompatible polymer or fibrin glue; a method for preparing an anti-adhesion material comprising complexing a biocompatible polymer or fibrin glue to decellularized tissues; an anti-adhesion material kit comprising decellularized tissues and a biocompatible polymer or fibrin glue; a substitute biomembrane comprising decellularized tissues and a biocompatible polymer or fibrin glue; a method for preparing a substitute biomembrane comprising complexing a biocompatible polymer or fibrin glue to decellularized tissues; and a substitute biomembrane kit comprising decellularized tissues and a biocompatible polymer or fibrin glue.

Claims (31)

1. An anti-adhesion material comprising decellularized tissues and a biocompatible polymer selected from the group consisting of alginic acid, gelatin, fibrin glue and polyethylene glycol,

wherein the decellularized tissues are those prepared by decellularizing biological tissues selected from the group consisting of pericardium, bladder, amnion, dura mater, peritoneum, diaphragm, fascia, small intestine submucosa and skin,

wherein the biocompatible polymer and the decellularized tissue are complexed to each other, and

wherein the anti-adhesion material reduces adhesion to biological tissues.

2. The anti-adhesion material of claim 1 wherein the decellularized tissues are the ones prepared by treating biological tissues with a high hydrostatic pressure or with a surfactant.

3. The anti-adhesion material of claim 2 wherein the treatment with a high hydrostatic pressure comprises applying a hydrostatic pressure of 50 to 1,500 MPa to biological tissues in a medium.

4. The anti-adhesion material of any one of claim 1 , claim 2 or claim 3 wherein the biocompatible polymer is a biocompatible polymer which naturally occurs.

5. The anti-adhesion material of any one of claim 1 , claim 2 or claim 3 wherein the biocompatible polymer is fibrin glue.

6. The anti-adhesion material of claim 1 wherein the complexation of the biocompatible polymer to the decellularized tissues is immersion or coating of the biocompatible polymer to the decellularized tissues.

7. The anti-adhesion material of any one of claim 1 , claim 2 , or claim 3 wherein the anti-adhesion material is an anti-adhesion membrane and a film thickness is 10 to 5,000 μm.

8. An anti-adhesion material kit comprising decellularized tissues and a biocompatible polymer selected from the group consisting of alginic acid, gelatin, fibrin glue and polyethylene glycol, wherein the decellularized tissues are those prepared by decellularizing biological tissues selected from the group consisting of pericardium, bladder, amnion, dura mater, peritoneum, diaphragm, fascia, small intestine submucosa and skin, wherein the biocompatible polymer and the decellularized tissue are complexed to each other, and wherein the anti-adhesion material reduces adhesion to biological tissues.

9. The kit of claim 8 wherein the decellularized tissues are the ones prepared by treating biological tissues with a high hydrostatic pressure or with a surfactant.

10. The kit of claim 9 wherein the treatment with a high hydrostatic pressure comprises applying a hydrostatic pressure of 50 to 1,500 MPa to biological tissues in a medium.

11. The kit of any one of claim 8 , claim 9 or claim 10 wherein the biocompatible polymer is fibrin glue.

12. The kit of claim 8 wherein the complexation of the biocompatible polymer to the decellularized tissues is immersion or coating of the biocompatible polymer to the decellularized tissues.

13. The kit of any one of claim 8 , claim 9 , or claim 10 wherein the anti-adhesion material is an anti-adhesion membrane and a film thickness is 10 to 5,000 μm.

14. A substitute biomembrane comprising decellularized tissues and a biocompatible polymer selected from the group consisting of alginic acid, gelatin, fibrin glue and polyethylene glycol, wherein the decellularized tissues are those prepared by decellularizing biological tissues selected from the group consisting of pericardium, bladder, amnion, dura mater, peritoneum, diaphragm, fascia, small intestine submucosa and skin, wherein the biocompatible polymer and the decellularized tissue are complexed to each other, and wherein the substitute biomembrane reduces adhesion to biological tissues.

15. The substitute biomembrane of claim 14 wherein the decellularized tissues are the ones prepared by treating biological tissues with a high hydrostatic pressure or with a surfactant.

16. The substitute biomembrane of claim 15 wherein the treatment with a high hydrostatic pressure comprises applying a hydrostatic pressure of 50 to 1,500 MPa to biological tissues in a medium.

17. The substitute biomembrane of any one of claim 14 , claim 15 or claim 16 wherein the biocompatible polymer is a biocompatible polymer which naturally occurs.

18. The substitute biomembrane of any one of claim 14 , claim 15 or claim 16 wherein the biocompatible polymer is fibrin glue.

19. The substitute biomembrane of claim 14 wherein the complexation of the biocompatible polymer to the decellularized tissues is immersion or coating of the biocompatible polymer to the decellularized tissues.

20. The substitute biomembrane of any one of claim 14 , claim 15 or claim 16 wherein a film thickness is 10 to 5,000 μm.

21. A method for preparing a substitute biomembrane comprising complexing a biocompatible polymer selected from the group consisting of alginic acid, gelatin, fibrin glue and polyethylene glycol, to decellularized tissues, wherein the decellularized tissues are those prepared by decellularizing biological tissues selected from the group consisting of pericardium, bladder, amnion, dura mater, peritoneum, diaphragm, fascia, small intestine submucosa and skin, wherein the biocompatible polymer and the decellularized tissue are complexed to each other, and wherein the substitute biomembrane reduces adhesion to biological tissues.

22. The method of claim 21 wherein the complexation is immersion or coating of the biocompatible polymer to the decellularized tissues.

23. A substitute biomembrane kit comprising decellularized tissues and a biocompatible polymer selected from the group consisting of alginic acid, gelatin, fibrin glue and polyethylene glycol, wherein the decellularized tissues are those prepared by decellularizing biological tissues selected from the group consisting of pericardium, bladder, amnion, dura mater, peritoneum, diaphragm, fascia, small intestine submucosa and skin, wherein the biocompatible polymer and the decellularized tissue are complexed to each other, and wherein the substitute biomembrane reduces adhesion to biological tissues.

24. The kit of claim 23 wherein the decellularized tissues are the ones prepared by treating biological tissues with a high hydrostatic pressure or with a surfactant.

25. The kit of claim 24 wherein the treatment with a high hydrostatic pressure comprises applying a hydrostatic pressure of 50 to 1,500 MPa to biological tissues in a medium.

26. The kit of any one of claim 23 wherein the biocompatible polymer is fibrin glue.

27. The kit of claim 23 wherein the complexation of the biocompatible polymer to the decellularized tissues is immersion or coating of the biocompatible polymer to the decellularized tissues.

28. The kit of any one of claim 23 wherein a film thickness of the substitute biomembrane is 10 to 5,000 μm.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2026
From: INSTITUTE OF SCIENCE TOKYO
To: ADEKA CORPORATION
Reel/Frame 073645/0321 →
MERGER AND DISSOLUTION Recorded Oct 9, 2025
From: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
To: INSTITUTE OF SCIENCE TOKYO
Reel/Frame 073063/0800 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2023
From: KM BIOLOGICS CO., LTD.
To: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY; SAPPORO MEDICAL UNIVERSITY; ADEKA CORPORATION
Reel/Frame 065386/0367 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2020
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: KM BIOLOGICS CO., LTD.
Reel/Frame 051520/0971 →
CHANGE OF ADDRESS OF ASSIGNEE Recorded Apr 15, 2019
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 050169/0778 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2017
From: SAGA, HIDEKI; UCHIDA, TAKANORI; TOKOROZAKI, SHOKO; HIWATARI, KEN-ICHIRO; OBARA, HARUKI; KISHIDA, AKIO; KIMURA, TSUYOSHI; NEGISHI, JUN; HIGAMI, TETSUYA; FUNAMOTO, SEIICHI
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE; ADEKA CORPORATION; NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY; SAPPORO MEDICAL UNIVERSITY
Reel/Frame 043533/0338 →
Priority Claims (1)
JP JP2015-049922 · Mar 12, 2015 · national
Continuity (1)
Related Publication 20180078679A1 · Mar 22, 2018